Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral insulin 338 tablet formulation versus insulin glargine in type 2 diabetes
2014-002716-16Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral insulin 338 tablet formulation with Insulin glargine (2 arms). Primary endpoint: Fasting plasma glucose. Started Mar 2015; status: completed.
02
Drugs
human insulininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-002716-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002716-16.